Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE - PERNIX THERAPEUTICS HOLDINGS, INC. | ptx_ex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 2, 2012
PERNIX THERAPEUTICS HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
|
Maryland
|
001-14494
|
33-0724736
|
||
|
(State or other jurisdiction
of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
10003 Woodloch Forest Drive
The Woodlands, TX
|
77354
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including area code: (832) 934-1825
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
Item 8.01
|
Other Events
|
On July 2, Pernix Therapeutics Holdings, Inc. (the “Company”) issued a press release announcing that it entered into a definitive agreement to acquire Great Southern Laboratories, a privately-held pharmaceutical contract manufacturing company located in Houston, Texas. Under the terms of the agreement, Pernix will pay approximately $4.9 million to acquire substantially all of the assets of Great Southern Laboratories and assume certain liabilities. The assets include buildings and land located in Houston. Pernix anticipates completing this transaction in July 2012. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
|
Item 9.01
|
Financial Statements and Exhibits
|
(d) Exhibits.
|
Exhibit Number
|
Description
|
|
|
Press release by Pernix Therapeutics Holdings, Inc. dated July 2, 2012.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
PERNIX THERAPEUTICS HOLDINGS, INC.
|
|||
|
Dated: July 12, 2012
|
By:
|
/s/ David P. Becker | |
|
David P. Becker
|
|||
|
Chief Financial Officer
|
|||